Emergent Biosolutions Inc (NYSE: EBS) is 4.29% higher on its value in year-to-date trading and has touched a low of $1.42 and a high of $15.10 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The EBS stock was last observed hovering at around $9.52 in the last trading session, with the day’s gains setting it 0.45%.
Currently trading at $9.97, the stock is 8.12% and 6.66% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.9 million and changing 4.73% at the moment leaves the stock 29.71% off its SMA200. EBS registered 391.13% gain for a year compared to 6-month loss of -17.05%. The firm has a 50-day simple moving average (SMA 50) of $9.3478 and a 200-day simple moving average (SMA200) of $7.6863.
The stock witnessed a 17.57% gain in the last 1 month and extending the period to 3 months gives it a 8.49%, and is -1.19% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.07% over the week and 6.84% over the month.
Emergent Biosolutions Inc (EBS) has around 1600 employees, a market worth around $540.21M and $1.13B in sales. Fwd P/E is 7.76. Profit margin for the company is -18.55%. Distance from 52-week low is 602.11% and -33.97% from its 52-week high. The company has generated returns on investments over the last 12 months (-17.68%).
with sales reaching $254.67M over the same period.The EPS is expected to grow by 86.57% this year, but quarterly earnings will post 5.18% year-over-year. Quarterly sales are estimated to shrink -7.93% in year-over-year returns.
174.0 institutions hold shares in Emergent Biosolutions Inc (EBS), with institutional investors hold 60.96% of the company’s shares. The shares outstanding are 54.10M, and float is at 52.75M with Short Float at 13.52%. Institutions hold 59.68% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 3.84 million shares valued at $26.18 million. The investor’s holdings represent 7.3551 of the EBS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 3.67 million shares valued at $25.0 million to account for 7.0234 of the shares outstanding. The other top investors are CHARLES SCHWAB INVESTMENT MANAGEMENT INC which holds 3.17 million shares representing 6.0656 and valued at over $21.59 million, while MORGAN STANLEY holds 2.3796 of the shares totaling 1.24 million with a market value of $8.47 million.
Emergent Biosolutions Inc (EBS) Insider Activity
The most recent transaction is an insider sale by DeGolyer Donald W, the company’s Director. SEC filings show that DeGolyer Donald W sold 25,000 shares of the company’s common stock on Nov 12 ’24 at a price of $10.91 per share for a total of $0.27 million. Following the sale, the insider now owns 0.11 million shares.
Emergent Biosolutions Inc disclosed in a document filed with the SEC on Nov 11 ’24 that White Marvin L (Director) sold a total of 14,287 shares of the company’s common stock. The trade occurred on Nov 11 ’24 and was made at $11.97 per share for $0.17 million. Following the transaction, the insider now directly holds 54092.0 shares of the EBS stock.
Still, SEC filings show that on Nov 12 ’24, DeGolyer Donald W (Director) Proposed Sale 25,000 shares at an average price of $11.77 for $0.29 million. The insider now directly holds shares of Emergent Biosolutions Inc (EBS).
